BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Patients with recent PMR(6 months or less) with a PMR-AS >17 and no oral or parenteral GCs
during the past 2 weeks (at least) will be included.
Treatment with oral baricitinib 4mg or placebo during 12 weeks and then, if PMR-AS≤10, they
will receive baricitinib 2 mg for 12 weeks and then will stop treatment.
No rescue is allowed before week 4 (visit 3) but patients may receive up to 2 intra-articular
or soft tissue injections of GCs until week 4 according to investigator's opinion.
From week 4 to week 12, steroids will be proposed as a rescue for both arms at investigators'
discretion and according to PMR-AS.